Abilify Maintena (Aripiprazole)

Abilify Maintena (aripiprazole) is an atypical antipsychotic used for the treatment of schizophrenia in adults, and for maintenance monotherapy treatment of bipolar I disorder in adults.

Recommended Dosage:
The recommended dosage is 400 mg administered monthly as a single injection. The dose can be reduced to 300 mg in patients with side effects. There are two ways to start treatment with Aripiprazole.

• 1-day initiation: Administer 2 separate intramuscular (IM) injections of Abilify Maintena 400 mg and a single oral dose of aripiprazole 20 mg.
• 14-day initiation: In conjunction with the first 400 mg dose, take 14 consecutive days of concurrent oral aripiprazole (10 mg to 20 mg) or current oral antipsychotic.

Dosage adjustments are required for missed doses. This therapeutic drug must be administered by intramuscular (IM) injection by a healthcare professional (HCP). Avoid administering it by any other route.

• Elderly patients with dementia-related psychosis may experience cerebrovascular side effects such as strokes or mini-strokes. This therapeutic drug increases this risk, and extreme caution must be considered when considering treatment in such patients.
• Neuroleptic Malignant Syndrome (NMS), a rare but life-threatening condition, may occur with this treatment. Symptoms include confusion, fever, muscle stiffness, and irregular heartbeat. Immediate medical attention is required, and treatment should be stopped in case NMS is suspected.
• Long-term use of this medicine can cause involuntary movements of the tongue, face, or limbs. This condition may be irreversible. The risk gets higher with duration of use, mainly in elderly patients, so ongoing assessment is important.
• This treatment may cause weight gain, high blood sugar, and increased cholesterol or triglyceride levels. Regular monitoring of blood glucose, weight, and lipid levels is required during treatment, particularly in children and adolescents.
• Aripiprazole 300 mg/400 mg may cause a sudden drop in blood pressure upon standing. This may cause dizziness or fainting. Patients should rise gradually from sitting or lying positions to reduce this probability, particularly elderly individuals.
• Treatment with this medicine can increase the risk of falls because of sedation, low blood pressure, or balance issues. Elderly patients, particularly those with other risk factors for falling, should be closely monitored throughout treatment.
• This medicine may reduce white blood cell (WBC) counts. This may lead to increased infection risk. Blood counts need to be monitored in those with a known history of low white blood cells (WBCs) or drug-induced leukopenia/neutropenia.
  Aripiprazole treatment may increase the probability of seizures, particularly in those with known seizure disorders or risk factors for seizures. Use this drug cautiously in these populations and report any seizure activity quickly to a healthcare provider.
• This treatment can affect the body’s potential to regulate temperature. This may lead to overheating. Patients must avoid excessive heat, strenuous exercise, or dehydration, particularly during warm weather or when physically active.
• Aripiprazole injection may cause swallowing difficulties. This could lead to aspiration pneumonia. Patients with swallowing complications or those at risk of choking should use this medicine carefully under proper medical supervision.
• Using it during pregnancy may harm the unborn baby, particularly in the third trimester. Babies exposed may show withdrawal signs and symptoms. This medicine should be used during pregnancy only if the potential benefit outweighs the potential risk.
• Aripiprazole passes into human breast milk and may affect a nursing baby. Women should discuss with their healthcare provider (HCP) whether to stop breastfeeding or stop treatment, weighing the benefits and risks in each case.

What documents are required to import ABILIFY MAINTENA to India?

ABILIFY MAINTENA (aripiprazole) injections can be imported by patients or government hospitals in the name of the patients only.
The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order get confirmed?

• The order will be confirmed only after the receipt of:
• A valid prescription from the Doctor
• Import permit if applicable

Is ABILIFY MAINTENA available in India?

ABILIFY MAINTENA (aripiprazole injections) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator, providing input

• On availability of Abilify Maintena in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

ABILIFY MAINTENA can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of ABILIFY MAINTENA (prescription medicines) to all locations in the world and India after fulfilling the legal requirements (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Abilify 300 mg/400 mg injection price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source ABILIFY MAINTENA (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient's address only from New Delhi, India.

What is the Generic Name for the trade name drug Abilify Maintena®?

Aripiprazole is the Generic Name for the trade name drug Abilify Maintena®.

What is the Manufacturer's Name of Abilify Maintena®?

Abilify Maintena® is manufactured by Otsuka Pharmaceutical Co., Ltd.

Is Abilify Maintena® approved by the FDA?

Yes, Abilify Maintena® is approved by the FDA. Date of first approval: February 28, 2013.

What is the dosage and form of Abilify Maintena® supplied?

Abilify Maintena is supplied for extended-release injectable suspension: 300 mg and 400 mg strength lyophilized powder for reconstitution in single-dose, pre-filled, dual-chamber syringe, and single-dose vial for intramuscular (IM) use.

What are the most common side effects of Abilify Maintena® 300 mg/400 mg injection?

The most common side effects of Abilify Maintena® are injection site pain, increased weight, akathisia, and sedation.

How much does Abilify Maintena® 300 mg/400 mg injection cost in India?

Abilify Maintena® is not yet approved in India. However, patients in India can legally access it through the provision Named Patient Program (NPP). Prices of Abilify Maintena injections may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Abilify Maintena 300 mg/400 mg cost in India, please call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

Can Abilify Maintena® 300 mg/400 mg injections be available in SAARC countries?

Apart from Gulf countries, Abilify Maintena® can be accessed through import provisions like Named Patient Import in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Abilify Maintena® injection in these countries. We help provide legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Abilify Maintena® 300 mg/400 mg injection online in India?

Yes, one can buy Abilify Maintena 300 mg/400 mg online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the legal supply of this therapeutic drug through legal channels.

What are the storage conditions of Abilify Maintena® 300 mg/400 mg injections?

Store pre-filled dual chamber syringe below 30°C [86°F]. Do not freeze. Protect the syringe from light by storing in the original package until the time of use. Store at 25°C (77°F), excursions permitted between 15°C and 30°C (59°F to 86°F).